Sarcoma / 2020 / Article / Fig 4

Research Article

Pharmacologic Inhibition of Ezrin-Radixin-Moesin Phosphorylation is a Novel Therapeutic Strategy in Rhabdomyosarcoma

Figure 4

NSC668394 inhibits the growth of RD xenograft in vivo. (a) Subcutaneous (SQ) RD tumor volumes in NSG mice subjected to daily intraperitoneal administration of either 20 mg/kg NSC668394 (n = 6) or DMSO (n = 6). (b) Orthotopic intramuscular (IM) RD tumor volumes in NSG mice subjected to daily intraperitoneal administration of 40 mg/kg NSC668394 (n = 10) or DMSO (n = 10). Total body weight of NSG mice bearing subcutaneous (c) and orthotopic (d) RD tumors on the indicated days. Negative values shown on the x-axis of total body weight plots represent days prior to starting NSC668384 treatment. Individual data points are represented as mean ± SEM. Asterisks represent a significant difference between treatment groups (, , , and ) for the given time point as determined by RM two-way ANOVA with Holm-Šídák multiple comparisons tests. Representative images of subcutaneous xenograft sections stained for Ki67 (e) or cleaved caspase-3 (f). Each stain was quantified as optical density using Fiji extension of ImageJ and plotted as bar graphs. Bars represent mean ± SEM, and asterisks represent a significant difference between treatment groups as determined by the unpaired t-test ( and ).
(a)
(b)
(c)
(d)
(e)
(f)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.